Displaying drugs 14676 - 14700 of 15205 in total
CRx-139
CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously. It is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. The synergistic combination containing low doses of the...
Investigational
Matched Description: … The synergistic combination containing low doses of the glucocorticoid steroid prednisolone and the antidepressant …
2-(4-HYDROXY-3-NITROPHENYL)ACETIC ACID
Experimental
Rivoglitazone
Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co.
Experimental
Investigational
4SC-203
4SC-203 has been used in trials studying the treatment of Acute Myeloid Leukemia.
Investigational
Cannabinor
Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.
Investigational
BMS-394136
BMS-394136 has been used in trials studying the diagnostic of Heart Diseases.
Investigational
LI-301
LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water. It has a novel mode of action combining both the light effect of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and antagonism...
Investigational
Matched Description: … of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and …
TPMPA
TPMPA ((1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid) is a selective antagonist of GABAC receptors (also known as GABA-ρ or GABAA-ρ receptors). GABAC receptors are found primarily in the retina, although they may be present in other tissues, including the hippocampus, spinal cord, superior colliculus, pituitary and the gut.[A245308,A245313] TPMPA is used as a pharmacological...
Experimental
Matched Description: … be present in other tissues, including the hippocampus, spinal cord, superior colliculus, pituitary and …
NLX-P101
NLX-P101, gene therapy is developed by Neurologix to treat Parkinson’s disease. The gene is glutamic acid decarboxylase (GAD), whose product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and targets the subthalamic nucleus (STN), which is overactive in patients with Parkinson’s disease. NLX-P101 is being evaluated as...
Investigational
Matched Description: … product synthesizes the major inhibitory neurotransmitter in the brain, (gamma)-aminobutyric acid (GABA), and …
Displaying drugs 14676 - 14700 of 15205 in total